Annals of Surgical Oncology

, Volume 16, Issue 3, pp 783–784 | Cite as

Exploring Clinical Implications of Mechanisms for Breast Cancer Local Recurrence

Breast Oncology

References

  1. 1.
    Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133–44PubMedCrossRefGoogle Scholar
  2. 2.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90PubMedCrossRefGoogle Scholar
  4. 4.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol 2008; 86:139–41PubMedCrossRefGoogle Scholar
  6. 6.
    Tuttle TM, Habermann EB, Grund EH et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007; 25:5203–9PubMedCrossRefGoogle Scholar
  7. 7.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 Mutations. Ann Surg Oncol 2008; 15:21–33PubMedCrossRefGoogle Scholar
  8. 8.
    Fatouros M, Roukos DH, Arampatzis I et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5:737–45PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197; author reply 198Google Scholar
  10. 10.
    Roukos DH, Agnanti NJ, Paraskevaidis E et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3PubMedGoogle Scholar
  11. 11.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRefGoogle Scholar
  12. 12.
    Ziogas D, Baltogiannis G, Fatouros M et al. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 2008; 247:714–5PubMedGoogle Scholar
  13. 13.
    Liakakos T, Roukos DH. More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008; 15:956–60PubMedCrossRefGoogle Scholar
  14. 14.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5PubMedCrossRefGoogle Scholar
  15. 15.
    Briasoulis E, Liakakos T, Dova L et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9PubMedCrossRefGoogle Scholar
  16. 16.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1PubMedCrossRefGoogle Scholar
  17. 17.
    Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 2002; 9:82830CrossRefGoogle Scholar
  18. 18.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9PubMedCrossRefGoogle Scholar
  19. 19.
    Smith MJ, Culhane AC, Killeen S, et al. Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery. Ann Surg Oncol 2008 Jul 12. [Epub ahead of print]Google Scholar
  20. 20.
    Pharoah PD, Antoniou AC, Easton DF et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796–803PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 2008; 26(26):4360–1CrossRefGoogle Scholar
  22. 22.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008; 358:1636; author reply 1636Google Scholar
  24. 24.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007; 6:308–12PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH.Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 2008; 8(5):587–97PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 2008. DOI: 10.1245/s10434-008-0109-6

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  1. 1.Department of Surgery, School of MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations